Literature DB >> 18182092

Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.

Agatha A van der Klaauw1, Nienke R Biermasz, Hendrieke C Hoftijzer, Alberto M Pereira, Johannes A Romijn.   

Abstract

OBJECTIVE: Cross-sectional studies have shown impaired quality of life (QoL) in patients in biochemical control of acromegaly. The aim of this study was to assess longitudinal changes in QoL in a homogenous cohort of patients with sustained biochemical control of acromegaly.
DESIGN: Prospective follow-up study. PATIENTS AND METHODS: QoL was assessed using four health-related QoL questionnaires (HADS, Hospital Anxiety and Depression Scale; MFI-20, Multidimensional Fatigue Index; NHP, Nottingham Health Profile; and SF-36, Short Form-36) and one disease-specific acromegaly quality of life (ACRO-QOL) questionnaire in 82 patients (43 men) with strict biochemical control of acromegaly, aged 56 years (range 29-84 years) at baseline and after 4 years of follow-up. The mean duration of controlled disease was 12 years (range 1-26 years).
RESULTS: During follow-up, scores in 5 of 26 QoL subscales significantly worsened: physical and social functioning (SF-36), physical fatigue (MFI-20), and psychological well-being and personal relations (ACRO-QOL). Using linear regression analysis, baseline item scores predicted the follow-up scores, indicating individual stability over time. Previous radiotherapy (n = 27, 33%) negatively influenced several QoL subscales at follow-up: energy, pain and social isolation (NHP), physical fatigue and reduction in activity and motivation (MFI-20), depression and total anxiety and depression scores (HADS) and physical performance (ACRO-QOL).
CONCLUSION: During 4 years of follow-up in patients with long-term biochemical control of ACRO-QOL is subtly, but progressively impaired. Radiotherapy was the predominant indicator of progressive impairment in QoL.

Entities:  

Mesh:

Year:  2008        PMID: 18182092     DOI: 10.1111/j.1365-2265.2007.03169.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  27 in total

1.  Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL.

Authors:  Cornelie D Andela; Nicolasine D Niemeijer; Margreet Scharloo; Jitske Tiemensma; Shaaji Kanagasabapathy; Alberto M Pereira; Noëlle G A Kamminga; Ad A Kaptein; Nienke R Biermasz
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 2.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire.

Authors:  Silvia Vandeva; Maria Yaneva; Emil Natchev; Atanaska Elenkova; Krasimir Kalinov; Sabina Zacharieva
Journal:  Endocrine       Date:  2015-01-06       Impact factor: 3.633

Review 4.  Update on quality of life in patients with acromegaly.

Authors:  Iris Crespo; Elena Valassi; Susan M Webb
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Impact of treatment satisfaction on quality of life of patients with acromegaly.

Authors:  Hasan Kepicoglu; Esra Hatipoglu; Irem Bulut; Ezgi Darici; Naz Hizli; Pinar Kadioglu
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

6.  The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.

Authors:  Kenichi Yoshida; Hidenori Fukuoka; Ryusaku Matsumoto; Hironori Bando; Kentaro Suda; Hitoshi Nishizawa; Genzo Iguchi; Wataru Ogawa; Susan M Webb; Yutaka Takahashi
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

7.  Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.

Authors:  Pamela U Freda; Murray B Gordon; Nicky Kelepouris; Peter Jonsson; Maria Koltowska-Haggstrom; A J van der Lely
Journal:  Endocr Pract       Date:  2015-03       Impact factor: 3.443

8.  Quality of life in female patients with acromegaly.

Authors:  O Celik; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

9.  Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?

Authors:  Panagiotis Anagnostis; Zoe A Efstathiadou; Maria Charizopoulou; Despina Selalmatzidou; Eleni Karathanasi; Maria Poulasouchidou; Marina Kita
Journal:  Endocrine       Date:  2014-02-08       Impact factor: 3.633

10.  Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly.

Authors:  Agatha A van der Klaauw; Jeroen J Bax; Ferdinand Roelfsema; Marcel P M Stokkel; Gabe B Bleeker; Nienke R Biermasz; Johannes W A Smit; Johannes A Romijn; Alberto M Pereira
Journal:  Pituitary       Date:  2009-06-12       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.